What is Novo Nordisk really asking for
Novo Nordisk is asking the FDA to crack down on unapproved, cheaper versions of weight loss drugs. But in the U.S. health care system, compounding pharmacies have long filled supply gaps for essential medications, including cancer treatments like cisplatin.
Often operating as nonprofits, these pharmacies provide more affordable alternatives when branded drugs are unavailable or too expensive. Compounded medications differ mainly in that they lack FDA approval and don’t undergo the same rigorous testing required for branded drugs.
“These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits,” Novo Nordisk wrote in a statement.
For some patients, however, compounded versions are the only affordable option. With high drug prices and insurance plans often not covering weight-loss treatments, many turn to compounded alternatives.
Invest in real estate without the headache of being a landlord
Imagine owning a portfolio of thousands of well-managed single family rentals or a collection of cutting-edge industrial warehouses. You can now gain access to a $1B portfolio of income-producing real estate assets designed to deliver long-term growth from the comforts of your couch.
The best part? You don’t have to be a millionaire and can start investing in minutes.
Learn MorePrioritizing health or protecting profits?
As Novo Nordisk intensifies its efforts to halt the compounding, questions arise about the true motivation behind its push. While the company says patient safety is its primary concern, critics argue the move may be more about protecting profits.
For Jennie Smith, a seamstress in Ohio, Wegovy’s $1,000 monthly price tag made it inaccessible. After researching, she found a compounded version through an online pharmacy, paying just $300 a month instead. While the key ingredient remains the same, this compounded version was produced by a pharmacy, not a pharmaceutical giant like Novo Nordisk.
Scott Brunner, CEO of the Alliance of Pharmacy Compounding, questioned why it took Novo Nordisk two and a half years to raise concerns about compounded versions.
“Novo Nordisk is so deeply concerned about patient safety that it’s taken them a whopping two-and-a-half years while their drug has been in shortage to conclude that the semaglutide API is so demonstrably difficult for compounding pharmacies to prepare that FDA now needs to place it off-limits for compounding?” Brunner wrote in a statement.
With the FDA’s upcoming decision, the accessibility of affordable alternatives hangs in the balance, potentially reshaping the future of weight-loss treatments and patient options.
The richest 1% use an advisor. Do you?
Wealthy people know that having money is not the same as being good with money. Advisor.com can help you shape your financial future and connect with expert guidance . A trusted advisor helps you make smart choices about investments, retirement savings, and tax planning.
Try it now
